Collegium Pharma (COLL) Provides 2025 Financial Guidance and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Collegium Provides 2025 Financial Guidance and Business Update
January 8, 2025 8:00 AM ESTProduct Revenues, Net Expected in the Range of $735 Million to $750 Million
Jornay PM® Net Revenue Expected to be in Excess of $135 Million
Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million
Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million
STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
In 2024, we executed on our priorities of maximizing the... More
